CR20150472A - USE OF PIRAZOLOPIRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kd-RELATED DISORDERS - Google Patents
USE OF PIRAZOLOPIRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kd-RELATED DISORDERSInfo
- Publication number
- CR20150472A CR20150472A CR20150472A CR20150472A CR20150472A CR 20150472 A CR20150472 A CR 20150472A CR 20150472 A CR20150472 A CR 20150472A CR 20150472 A CR20150472 A CR 20150472A CR 20150472 A CR20150472 A CR 20150472A
- Authority
- CR
- Costa Rica
- Prior art keywords
- pi3kd
- pirazolopirimidine
- derivatives
- treatment
- related disorders
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La presente solicitud proporciona metodos para tratartrastornos relacionados con PI3Kd utilizando compuestos de laformula I, o sales farmaceuticamente aceptables de los mismos.The present application provides methods for treating disorders related to PI3Kd using compounds of formula I, or pharmaceutically acceptable salts thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361771480P | 2013-03-01 | 2013-03-01 | |
PCT/US2014/019372 WO2014134426A1 (en) | 2013-03-01 | 2014-02-28 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20150472A true CR20150472A (en) | 2016-01-04 |
Family
ID=50288319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20150472A CR20150472A (en) | 2013-03-01 | 2015-09-10 | USE OF PIRAZOLOPIRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kd-RELATED DISORDERS |
Country Status (32)
Country | Link |
---|---|
US (5) | US9932341B2 (en) |
EP (3) | EP3632442B1 (en) |
JP (4) | JP6545106B2 (en) |
KR (4) | KR20230145517A (en) |
CN (2) | CN109010343A (en) |
AR (1) | AR094964A1 (en) |
AU (4) | AU2014223257B2 (en) |
BR (1) | BR112015020941A2 (en) |
CA (1) | CA2901993C (en) |
CL (1) | CL2015002442A1 (en) |
CR (1) | CR20150472A (en) |
CY (1) | CY1122712T1 (en) |
DK (1) | DK2961410T3 (en) |
EA (2) | EA202192151A1 (en) |
ES (2) | ES2774436T3 (en) |
HK (1) | HK1221398A1 (en) |
HR (1) | HRP20200263T1 (en) |
HU (1) | HUE047719T2 (en) |
IL (5) | IL301180A (en) |
LT (1) | LT2961410T (en) |
MX (2) | MX367713B (en) |
MY (1) | MY177875A (en) |
PE (1) | PE20151996A1 (en) |
PH (2) | PH12015501920A1 (en) |
PL (1) | PL2961410T3 (en) |
PT (1) | PT2961410T (en) |
RS (1) | RS59958B1 (en) |
SG (3) | SG10201707130UA (en) |
SI (1) | SI2961410T1 (en) |
TW (4) | TWI687220B (en) |
UA (1) | UA119641C2 (en) |
WO (1) | WO2014134426A1 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2845856A1 (en) | 2009-06-29 | 2015-03-11 | Incyte Corporation | Pyrimidinones as PI3K inhibitors |
BR112014004971B1 (en) | 2011-09-02 | 2021-02-09 | Incyte Holdings Corporation | heterocyclyl amine compounds, their pharmaceutical composition and their uses |
AR090548A1 (en) | 2012-04-02 | 2014-11-19 | Incyte Corp | BICYCLIC AZAHETEROCICLOBENCILAMINS AS PI3K INHIBITORS |
US9278950B2 (en) | 2013-01-14 | 2016-03-08 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
BR122019024759B1 (en) | 2013-01-15 | 2022-02-08 | Incyte Holdings Corporation | COMPOUNDS OF THIAZOLACARBOXAMIDES AND PYRIDINECARBOXAMIDE, COMPOSITION COMPRISING THE SAME, METHOD OF INHIBITION OF THE ENZYME PIM1, PIM2, OR PIM3, AND USES OF SUCH COMPOUNDS |
TWI687220B (en) * | 2013-03-01 | 2020-03-11 | 美商英塞特控股公司 | Use of pyrazolopyrimidine derivatives for the treatment of pi3kδ related disorders |
JP2016528298A (en) | 2013-08-23 | 2016-09-15 | インサイト・コーポレイションIncyte Corporation | Furopyridine and thienopyridinecarboxamide compounds useful as PIM kinase inhibitors |
RS61058B1 (en) | 2014-04-08 | 2020-12-31 | Incyte Corp | Treatment of b-cell malignancies by a combination jak and pi3k inhibitor |
WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
SI3831833T1 (en) * | 2015-02-27 | 2023-03-31 | Incyte Holdings Corporation | Processes for the preparation of a pi3k inhibitor |
WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
TWI734699B (en) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Salts of a pim kinase inhibitor |
US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
MA43169B1 (en) | 2015-11-06 | 2022-05-31 | Incyte Corp | Heterocyclic compounds as pi3k-gamma inhibitors |
TW201734003A (en) | 2016-01-05 | 2017-10-01 | 英塞特公司 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors |
KR102375929B1 (en) | 2016-03-31 | 2022-03-16 | 온크터널 테라퓨틱스, 인코포레이티드. | Indoline analogs and uses thereof |
TW201803871A (en) | 2016-06-24 | 2018-02-01 | 英塞特公司 | Heterocyclic compounds as PI3K-[gamma] inhibitors |
HUE056615T2 (en) | 2017-10-18 | 2022-02-28 | Incyte Corp | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors |
WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
KR102574564B1 (en) * | 2018-01-10 | 2023-09-04 | 이도르시아 파마슈티컬스 리미티드 | 2,4,6,7-tetrahydro-pyrazolo[4,3-D]pyrimidin-5-one derivatives and related compounds as C5A receptor modulators for the treatment of vasculitis and inflammatory diseases |
MX2020009228A (en) | 2018-03-08 | 2021-01-08 | Incyte Corp | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS. |
SG11202011680YA (en) | 2018-06-01 | 2020-12-30 | Incyte Corp | Dosing regimen for the treatment of pi3k related disorders |
TWI727392B (en) * | 2018-08-13 | 2021-05-11 | 美商基利科學股份有限公司 | Thiadiazole irak4 inhibitors |
CN110833552A (en) * | 2018-08-15 | 2020-02-25 | 广西梧州制药(集团)股份有限公司 | Use of pyrazolopyrimidine derivatives for the treatment of lupus nephritis |
WO2020051169A1 (en) * | 2018-09-05 | 2020-03-12 | Incyte Corporation | Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor |
WO2022115762A1 (en) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
WO2022115120A1 (en) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
CN112808550B (en) * | 2020-12-28 | 2021-10-01 | 青岛理工大学 | Degraded immune bionic protection interface for ocean engineering and preparation method thereof |
TW202329976A (en) | 2021-12-16 | 2023-08-01 | 美商英塞特公司 | Topical formulations of pi3k-delta inhibitors |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
ES2342240T3 (en) | 1998-08-11 | 2010-07-02 | Novartis Ag | ISOQUINOLINE DERIVATIVES WITH ACTIVITY INHIBITED BY ANGIOGENIA. |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
US20040089753A1 (en) | 2000-06-28 | 2004-05-13 | Holland Simon Joseph | Wet milling process |
AU2002337142B2 (en) | 2001-09-19 | 2007-10-11 | Aventis Pharma S.A. | Indolizines as kinase protein inhibitors |
EP1441737B1 (en) | 2001-10-30 | 2006-08-09 | Novartis AG | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
AR037647A1 (en) | 2002-05-29 | 2004-12-01 | Novartis Ag | USED DIARILUREA DERIVATIVES FOR THE TREATMENT OF DEPENDENT DISEASES OF THE PROTEIN KINase |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
AR042052A1 (en) | 2002-11-15 | 2005-06-08 | Vertex Pharma | USEFUL DIAMINOTRIAZOLS AS INHIBITORS OF PROTEINQUINASES |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
PE20050952A1 (en) | 2003-09-24 | 2005-12-19 | Novartis Ag | DERIVATIVES OF ISOQUINOLINE AS INHIBITORS OF B-RAF |
BRPI0511978A (en) | 2004-06-10 | 2008-01-22 | Irm Llc | compounds and compositions as protein kinase inhibitors |
JP2008520612A (en) | 2004-11-24 | 2008-06-19 | ノバルティス アクチエンゲゼルシャフト | Combination of JAK inhibitor and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitor |
WO2009026701A1 (en) | 2007-08-29 | 2009-03-05 | Methylgene Inc. | Sirtuin inhibitors |
AR073651A1 (en) * | 2008-09-24 | 2010-11-24 | Novartis Ag | GALENIC FORMULATIONS OF ORGANIC COMPOUNDS |
JP5731978B2 (en) * | 2008-09-26 | 2015-06-10 | インテリカイン, エルエルシー | Heterocyclic kinase inhibitor |
EP2845856A1 (en) | 2009-06-29 | 2015-03-11 | Incyte Corporation | Pyrimidinones as PI3K inhibitors |
SI2470546T1 (en) | 2009-08-28 | 2013-12-31 | Takeda Pharmaceutical Company Limited | Hexahydrooxazinopteridine compounds for use as mtor inhibitors |
US8680108B2 (en) | 2009-12-18 | 2014-03-25 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors |
WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
AR081823A1 (en) | 2010-04-14 | 2012-10-24 | Incyte Corp | FUSIONATED DERIVATIVES AS PI3Kd INHIBITORS |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
US9096600B2 (en) | 2010-12-20 | 2015-08-04 | Incyte Corporation | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
USRE47009E1 (en) | 2011-02-01 | 2018-08-28 | The Children's Hospital Of Philadelphia | HDAC inhibitors and therapeutic methods using the same |
US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
BR112014004971B1 (en) | 2011-09-02 | 2021-02-09 | Incyte Holdings Corporation | heterocyclyl amine compounds, their pharmaceutical composition and their uses |
AR090548A1 (en) | 2012-04-02 | 2014-11-19 | Incyte Corp | BICYCLIC AZAHETEROCICLOBENCILAMINS AS PI3K INHIBITORS |
TWI687220B (en) * | 2013-03-01 | 2020-03-11 | 美商英塞特控股公司 | Use of pyrazolopyrimidine derivatives for the treatment of pi3kδ related disorders |
WO2015191677A1 (en) * | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
SI3831833T1 (en) * | 2015-02-27 | 2023-03-31 | Incyte Holdings Corporation | Processes for the preparation of a pi3k inhibitor |
SG11202011680YA (en) * | 2018-06-01 | 2020-12-30 | Incyte Corp | Dosing regimen for the treatment of pi3k related disorders |
WO2020102150A1 (en) * | 2018-11-13 | 2020-05-22 | Incyte Corporation | Heterocyclic derivatives as pi3k inhibitors |
-
2014
- 2014-02-27 TW TW108100664A patent/TWI687220B/en active
- 2014-02-27 TW TW110124946A patent/TW202214254A/en unknown
- 2014-02-27 TW TW109104878A patent/TWI736135B/en active
- 2014-02-27 TW TW103106906A patent/TWI657090B/en active
- 2014-02-28 AU AU2014223257A patent/AU2014223257B2/en active Active
- 2014-02-28 WO PCT/US2014/019372 patent/WO2014134426A1/en active Application Filing
- 2014-02-28 PT PT147107395T patent/PT2961410T/en unknown
- 2014-02-28 CA CA2901993A patent/CA2901993C/en active Active
- 2014-02-28 ES ES14710739T patent/ES2774436T3/en active Active
- 2014-02-28 ES ES19208523T patent/ES2945212T3/en active Active
- 2014-02-28 CN CN201810796220.8A patent/CN109010343A/en active Pending
- 2014-02-28 SI SI201431449T patent/SI2961410T1/en unknown
- 2014-02-28 US US14/193,481 patent/US9932341B2/en active Active
- 2014-02-28 SG SG10201707130UA patent/SG10201707130UA/en unknown
- 2014-02-28 EP EP19208523.1A patent/EP3632442B1/en active Active
- 2014-02-28 HU HUE14710739A patent/HUE047719T2/en unknown
- 2014-02-28 KR KR1020237033761A patent/KR20230145517A/en not_active Application Discontinuation
- 2014-02-28 KR KR1020217027697A patent/KR102454308B1/en active IP Right Grant
- 2014-02-28 JP JP2015560346A patent/JP6545106B2/en active Active
- 2014-02-28 LT LTEP14710739.5T patent/LT2961410T/en unknown
- 2014-02-28 PL PL14710739T patent/PL2961410T3/en unknown
- 2014-02-28 EA EA202192151A patent/EA202192151A1/en unknown
- 2014-02-28 PE PE2015001833A patent/PE20151996A1/en not_active Application Discontinuation
- 2014-02-28 MY MYPI2015002108A patent/MY177875A/en unknown
- 2014-02-28 DK DK14710739.5T patent/DK2961410T3/en active
- 2014-02-28 KR KR1020227035039A patent/KR102586858B1/en active IP Right Grant
- 2014-02-28 MX MX2015011273A patent/MX367713B/en active IP Right Grant
- 2014-02-28 EP EP14710739.5A patent/EP2961410B1/en active Active
- 2014-02-28 EP EP23161858.8A patent/EP4233869A3/en active Pending
- 2014-02-28 BR BR112015020941A patent/BR112015020941A2/en not_active Application Discontinuation
- 2014-02-28 KR KR1020157027010A patent/KR102298150B1/en active IP Right Grant
- 2014-02-28 AR ARP140100679A patent/AR094964A1/en unknown
- 2014-02-28 SG SG11201506654UA patent/SG11201506654UA/en unknown
- 2014-02-28 CN CN201480021187.1A patent/CN105120871B/en active Active
- 2014-02-28 SG SG10201912275YA patent/SG10201912275YA/en unknown
- 2014-02-28 UA UAA201509435A patent/UA119641C2/en unknown
- 2014-02-28 RS RS20200176A patent/RS59958B1/en unknown
- 2014-02-28 EA EA201591612A patent/EA201591612A1/en unknown
- 2014-02-28 IL IL301180A patent/IL301180A/en unknown
-
2015
- 2015-08-24 IL IL240784A patent/IL240784B/en not_active IP Right Cessation
- 2015-08-28 MX MX2019010422A patent/MX2019010422A/en unknown
- 2015-08-31 CL CL2015002442A patent/CL2015002442A1/en unknown
- 2015-09-01 PH PH12015501920A patent/PH12015501920A1/en unknown
- 2015-09-10 CR CR20150472A patent/CR20150472A/en unknown
-
2016
- 2016-06-07 HK HK16106523.5A patent/HK1221398A1/en unknown
-
2018
- 2018-03-02 US US15/910,708 patent/US20190040067A1/en not_active Abandoned
- 2018-11-14 AU AU2018264053A patent/AU2018264053B2/en active Active
-
2019
- 2019-04-25 JP JP2019084393A patent/JP6776399B2/en active Active
- 2019-06-11 PH PH12019501321A patent/PH12019501321B1/en unknown
- 2019-07-04 IL IL267853A patent/IL267853B/en active IP Right Grant
-
2020
- 2020-02-17 HR HRP20200263TT patent/HRP20200263T1/en unknown
- 2020-02-26 CY CY20201100177T patent/CY1122712T1/en unknown
- 2020-05-19 IL IL274771A patent/IL274771A/en unknown
- 2020-07-31 AU AU2020210278A patent/AU2020210278B2/en active Active
- 2020-10-07 JP JP2020169551A patent/JP7189185B2/en active Active
-
2021
- 2021-06-13 IL IL283943A patent/IL283943B2/en unknown
- 2021-06-30 US US17/364,551 patent/US20220106318A1/en active Pending
- 2021-06-30 US US17/364,695 patent/US20210332059A1/en active Pending
- 2021-06-30 US US17/364,585 patent/US20220119393A1/en active Pending
-
2022
- 2022-08-16 AU AU2022218495A patent/AU2022218495A1/en active Pending
- 2022-12-01 JP JP2022192954A patent/JP2023036609A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20150472A (en) | USE OF PIRAZOLOPIRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kd-RELATED DISORDERS | |
CY1123637T1 (en) | ARGININE METHYL TRANSFER INHIBITORS AND THEIR USES | |
CU20160188A7 (en) | INDAZOLE COMPOUNDS SUBSTITUTED AS IRAK4 INHIBITORS | |
DOP2015000274A (en) | CHEMICAL COMPOUNDS | |
CL2017001050A1 (en) | New methyl quinoline compounds useful for inhibiting microsomal e2 prostaglandin synthase-1 | |
MX2018000396A (en) | Substituted aza compounds as irak-4 inhibitors. | |
NI201500140A (en) | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | |
ECSP16005566A (en) | SULFONAMIDES AS SODIUM CHANNEL MODULATORS | |
SV2015005066A (en) | BIARIL-AMIDA COMPOUNDS AS CINASA INHIBITORS | |
DOP2015000158A (en) | PRMT5 INHIBITORS AND THEIR USES | |
CR20160523A (en) | IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE TO TREAT CANCER | |
CL2014001793A1 (en) | Compounds derived from substituted 1,3,5-triazines and their salts, as inhibitors of mutant idh2; pharmaceutical composition that includes them; and its use for the treatment of cancer. | |
CU24603B1 (en) | SUBSTITUTED DIAZABICYCLIC IMIDAZOPYRIMIDINES USEFUL IN THE TREATMENT OF RESPIRATORY DISORDERS | |
NI201800042A (en) | NEW DERIVATIVES OF PIRROLO [2,3-D] PYRIMIDINE AS DUAL INHIBITORS OF DYRK1 / CLK1 | |
DOP2015000170A (en) | CHEMICAL COMPOUNDS | |
CR20150378A (en) | TETRACYCLIC COMPOUNDS REPLACED WITH HETEROCICLE AND METHODS OF USE OF THE SAME FOR THE TREATMENT OF VIVIC DISEASES | |
CR20170077A (en) | OPTIONALLY CONDENSED HEREROCICLYL PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGICAL AND AUTOINMUNITY DISEASES | |
UY35274A (en) | COMPOUNDS AND METHODS TO TREAT BACTERIAL INFECTIONS | |
UY36875A (en) | BROMODOMINIUM INHIBITING COMPOSITIONS FOR THE TREATMENT OF VARIOUS DISEASES | |
CL2019002900A1 (en) | Benzoazepine analogs as bruton tyrosine kinase inhibitors. | |
ECSP16008797A (en) | DERIVATIVES OF HETEROBICICLOARIL AS RORC2 INHIBITORS AND METHODS OF USE OF THE SAME | |
UY35359A (en) | 7-OXO-PIRIDO [2,3-d] SUBSTITUTED PYRIMIDINS AND METHODS OF USE | |
UY35746A (en) | SUBSTITUTED PHENYLALANINE DERIVATIVES | |
EA201491227A1 (en) | NEW MORFOLINIL DERIVATIVES SUITABLE FOR USING AS MOGAT-2 INHIBITORS | |
EA201790687A1 (en) | QUINOLINCARBOXAMIDE FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA |